One hundred and sixty patients with a mean age of 41.1 +/- 15 years were enrolled in this study and qualified by having clinical features of APS in addition to being triple positive for APS, i.e. they had all three antiphospholipid (aPL) antibodies; lupus anticoagulant (LA), anticardiolipin (aCL), and anti-b2-Glycoprotein I (ab2GPI) antibodies. The gene discussed is ACLY; the disease is autoimmune polyendocrinopathy.